You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
轮证日报 |华虹半导体创历史新高,认购证涨40%
uSMART盈立智投 12-18 16:55

今日市场短评

恒指午后进一步下挫,最多跌超300点后站稳,截至收市,恒指收跌0.67%,报26498.6点。

盘面上,科技股普遍回调,大金融股领跌;光伏、煤炭等热门板块续走强;汽车、电信板块逆市走高。

个股方面,京东健康收涨6%,盘中股价首次站上150港元;赣锋锂业涨8.3%破顶;中国电信涨5%。中芯国际跌5.2%,传美国政府计划将中芯国际加入黑名单;美团跌2.3%;青岛啤酒股份跌4.3%,遭大股东复星国际减持套现。

窝轮(认股证)焦点

信义光能(00968)信光认购证(29935)到期日:2021年4月杠杆:4.45倍

麦格理:上调信义光能目标价至17.9港元 评级维持跑赢大市麦格理发表报告指,工信部早前公布有意将太阳能玻璃的产能扩张限制移除,为回应最新的政策改变,信义光能公布进行第二轮配股,以每股13港元配售3亿股股份,筹资约39亿港元。该行表示,是次监管改变将鼓励更多新产能,预期太阳能玻璃市场在2022年後的供应将会增加。而信义光能在太阳能玻璃行业仍是最有竞争力的市占增加者,该行喜好集团对最新政策变化的反应迅速,认为其行动是有效地向较落後的企业发出讯息,即在集团之外的任何进一步产能扩张,或导致未来的盈利能力下降。麦格理上调信义光能股份目标价13%,由15.8港元升至17.9港元,评级维持跑赢大市。

华虹半导体(01347)

华虹认购证(16177)到期日:2021年3月杠杆:3.54倍

华虹半导体涨超5%破顶,昨日工信部等四部委明确国家鼓励的集成电路企业和软件企业的企业所得税减免政策;早前方正证券亦撰文予华虹半导体“强烈推荐”评级。

消息面上,内地财政部、税务总局、发展改革委及工信部就宽减晶片行业所得税公告落实安排,晶片企业最高可免10年所得税,相关措施在2020年1月1日生效。

公告指,国家鼓励的集成电路线宽小於28纳米,且经营期在15年以上的集成电路生产企业或项目,第一年至第十年免徵企业所得税;集成电路线宽小於65纳米, 且经营期在15年以上的集成电路生产企业或项目,第一年至第五年免徵企业所得税,第六年至第十年按照25%的法定税率减半徵收企业所得税;集成电路线宽小 於130纳米,且经营期在10年以上的集成电路生产企业或项目,第一年至第二年免徵企业所得税,第三年至第五年按照25%的法定税率减半徵收企业所得税。

| 牛熊证焦点

吉利汽车(00175)

吉利牛证(55699)到期日:2021年8月回收价:20.5杠杆:6.76倍

麦格理上调吉利汽车今明两年每股盈测分别2%及9%,以反映价格趋势胜预期、旗下高端品牌“领克”表现强劲,以及稳定的产品周期,相信公司新能源车业务转势预期下,盈利增长动力料续支持估值重评,目标价由14.5港元大升至28.4港元,评级由“中性”升至“跑赢大市”,属行业首选股之一。

药明生物(02269)

药明牛证(52454)到期日:2021年6月回收价:72.9

杠杆:5.14倍

我国目前已有5支新冠病毒疫苗在进行Ⅲ期临床试验,数量位于全球前列。国务院联防联控机制科研攻关组疫苗研发专班工作组组长、国家卫健委医药卫生科技发展研究中心主任郑忠伟接受新华社记者专访时说,“疫苗研发已经进入冲刺阶段,我们处于全球第一方阵,但不为第一而抢跑。”

麦格理发表研报指,第五轮医保谈判(NRDL)正式于北京举行,建议投资者在医保谈判结束后捞底。麦格理预期,药企及生物技术公司仍可能会在研发方面投入更多的资金来开发新产品,以减轻政策影响,预期药明生物应继续受惠,予“跑赢大市”评级及目标价87.34港元,首选信达生物,予“跑赢大市”评级及目标价76.01港元。

衍生品资金流入/流出

 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account